The influence of aqueous content in small scale salt screening-Improving hit rate for weakly basic, low solubility drugs

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 1, 2010, Pages 23-30

  Tarsa, Peter B ^a   Towler, Christopher S ^b   Woollam, Grahame ^b   Berghausen, Jörg ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Crystallization; High throughput; Low water solubility; Physical form selection; Salt screening

Indexed keywords

ATROPINE; CINNARIZINE; CLOTRIMAZOLE; ITRACONAZOLE; SODIUM CHLORIDE; DRUG; INORGANIC SALT; WATER;

ARTICLE; BIOAVAILABILITY; CRYSTALLIZATION; DISSOLUTION; DRUG SOLUBILITY; PRIORITY JOURNAL; SCREENING; CHEMICAL STRUCTURE; CHEMISTRY; SOLUBILITY; X RAY CRYSTALLOGRAPHY;

CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; SALTS; SOLUBILITY; WATER;

EID: 77954759851     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.05.009     Document Type: Article

References (22)

1. Aaltonen J., Alleso M., Mirza S., Koradia V., Gordon K.C., Rantanen J. Solid form screening-a review. Eur. J. Pharm. Biopharm. 2009, 71:23-37.
2. Bastin R.J., Bowker M.J., Slater B.J. Salt selection and optimization procedures for pharmaceutical new chemical entities. Org. Proc. Res. Dev. 2000, 4:427-435.
3. Berge S.M., Bighley L.D., Monkhouse D.C. Pharmaceutical salts. J. Pharm. Sci. 1977, 66:1-19.
4. Black S.N., Collier E.A., Davey R.J., Roberts R.J. Structure, solubility, screening, and synthesis of molecular salts. J. Pharm. Sci. 2007, 96:1053-1068.
5. Chiang P.C., South S.A., Daniels J.S., Anderson D.R., Wene S.P., Albin L.A., Mourey R.J., Selbo J.G. Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in rats. J. Pharm. Sci. 2009, 98:248-256.
6. Davies G. Changing the salt, changing the drug. Pharm. J. 2001, 266:322-323.
7. Gardner C.R., Walsh C.T., Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 2004, 3:926-934.
8. Garrido G., de Nogales V., Rafols C., Bosch E. Acidity of several polyprotic acids, amiodarone and quetiapine hemifumarate in pure methanol. Talanta 2007, 73:115-120.
9. Garrido G., Koort E., Rafols C., Bosch E., Rodima T., Leito I., Roses M. Acid-base equilibria in nonpolar media. Absolute pKa scale of bases in tetrahydrofuran. J. Org. Chem. 2006, 71:9062-9067.
10. Garrido G., Rafols C., Bosch E. Acidity constants in methanol/water mixtures of polycarboxylic acids used in drug salt preparations-potentiometric determination of aqueous pKa values of quetiapine formulated as hemifumarate. Eur. J. Pharm. Sci 2006, 28:118-127.
11. Gould P.L. Salt selection for basic drugs. Int. J. Pharm. 1986, 33:201-217.
12. Gross T.D., Schaab K., Ouellette M., Zook S., Reddy J.P., Shurtleff A., Sacaan A.I., Alebic-Kolbah T., Bozigian H. An approach to early-phase salt selection; application to NBI-75043. Org. Proc. Res. Dev. 2007, 11:365-377.
13. Hilfiker R., Berghausen J., Blatter F., Burkhard A., De Paul S., Freiermuth B., Geoffroy A., Hofmeier U., Marcolli C., Siebenhaar B., Szelagiewicz M., Vit A., von Raumer M. Polymorphism-integrated approach from high-throughput screening to crystallization optimization. J. Therm. Anal. Calorim. 2003, 73:429-440.
14. Mahler D.A., Donohue J.F., Barbee R.A., Goldman M.D., Gross N.J., Wisniewski M.E., Yancey S.W., Zakes B.A., Rickard K.A., Anderson W.H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, (April):957-965.
15. Morissette S.L., Almarsson O., Peterson M.L., Remenar J.F., Read M.J., Lemmo A.V., Ellis S., Cima M.J., Gardner C.R. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev. 2004, 56:275-300.
16. Morris K.R., Fakes M.G., Thakur A.B., Newman A.W., Singh A.K., Venit J.J., Spagnuolo C.J., Serajuddin A.T.M. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 1994, 105:209-217.
17. Paulekuhn G.S., Dressman J.B., Saal C. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J. Med. Chem. 2007, 50:6665-6672.
18. Remenar J.F., MacPhee J.M., Larson B.K., Tyagi V.A., Ho J.H., Mcllroy D.A., Hickey M.B., Shaw P.B., Almarsson O. Salt selection and simultaneous polymorphism assessment via high-throughput crystallization. The case of sertraline. Org. Proc. Res. Dev. 2003, 7:990-996.
19. Rived F., Canals I., Bosch E., Roses M. Acidity in methanol-water. Anal. Chim. Acta 2001, 439:315-333.
20. Serajuddin A.T.M. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 2007, 59:603-616.
21. Stahl P.H., Wermuth C.G. Monographs on acids and bases. Handbook of Pharmaceutical Salts: Properties, Selection, and Use 2002, 265-327. Wiley-VCH, Weinheim. P.H. Stahl, C.G. Wermuth (Eds.).
22. Tong W.Q., Whitesell G. In situ salt screening-a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol. 1998, 3:215-223.